IL108147A - Compositions of the ethyl ester of l-dopa and their preparation - Google Patents

Compositions of the ethyl ester of l-dopa and their preparation

Info

Publication number
IL108147A
IL108147A IL10814793A IL10814793A IL108147A IL 108147 A IL108147 A IL 108147A IL 10814793 A IL10814793 A IL 10814793A IL 10814793 A IL10814793 A IL 10814793A IL 108147 A IL108147 A IL 108147A
Authority
IL
Israel
Prior art keywords
dopa
ethyl ester
pharmaceutical composition
composition
solution
Prior art date
Application number
IL10814793A
Other languages
English (en)
Other versions
IL108147A0 (en
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of IL108147A0 publication Critical patent/IL108147A0/xx
Publication of IL108147A publication Critical patent/IL108147A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
IL10814793A 1992-12-24 1993-12-22 Compositions of the ethyl ester of l-dopa and their preparation IL108147A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (2)

Publication Number Publication Date
IL108147A0 IL108147A0 (en) 1994-04-12
IL108147A true IL108147A (en) 1998-09-24

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10814793A IL108147A (en) 1992-12-24 1993-12-22 Compositions of the ethyl ester of l-dopa and their preparation

Country Status (20)

Country Link
US (2) US5354885A (fr)
EP (2) EP0867179B1 (fr)
JP (1) JPH07285860A (fr)
CN (1) CN1083262C (fr)
AT (2) ATE178793T1 (fr)
AU (1) AU684053B2 (fr)
CA (1) CA2112160A1 (fr)
CY (1) CY2214B1 (fr)
DE (2) DE69329400T2 (fr)
DK (2) DK0610595T3 (fr)
ES (2) ES2132170T3 (fr)
FI (1) FI107994B (fr)
GR (2) GR3030073T3 (fr)
HU (1) HU218906B (fr)
IL (1) IL108147A (fr)
LV (1) LV12766B (fr)
NO (1) NO305932B1 (fr)
NZ (1) NZ250541A (fr)
PT (1) PT867179E (fr)
ZA (1) ZA939573B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DK1063981T3 (da) * 1998-03-16 2002-10-14 Somerset Pharmaceuticals Inc Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
NZ512027A (en) * 1998-11-10 2004-04-30 Teva Pharma Dispersible compositions containing L-dopa ethyl ester
WO2000027801A1 (fr) * 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Procede de production d'un ester ethylique de l-dopa
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
RU2173150C1 (ru) * 2000-06-27 2001-09-10 Васильев Виталий Николаевич Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
WO2003041646A2 (fr) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Sels de l-dopa ethylester et leurs utilisations
AU2002346372A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
AU2003218307B8 (en) 2002-03-20 2006-08-31 Alkermes, Inc. Pulmonary delivery for levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (fr) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives d'amide l-dopa et utilisations de ceux-ci
JP2006524708A (ja) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
CA2642593C (fr) * 2006-02-17 2014-11-04 Birds Pharma Gmbh Berolina Innovative Research & Development Services Derives de catecholamine deuteries et medicaments comprenant de tels composes
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
PT3341380T (pt) * 2015-08-27 2019-12-19 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
LT4039093T (lt) 2021-02-09 2023-11-10 Biobab R&D, S.L. 3,4-dihidroksifenilalanino (dopa) enantiomerų naudojimas ir metodas, skirtas augalų patrauklumui naudingiesiems vabzdžiams didinti

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Also Published As

Publication number Publication date
HU9303748D0 (en) 1994-04-28
CN1083262C (zh) 2002-04-24
EP0867179A1 (fr) 1998-09-30
GR3030073T3 (en) 1999-07-30
EP0610595A2 (fr) 1994-08-17
US5354885A (en) 1994-10-11
LV12766B (en) 2002-03-20
EP0867179B1 (fr) 2000-09-06
FI107994B (fi) 2001-11-15
ATE178793T1 (de) 1999-04-15
LV12766A (lv) 2001-12-20
EP0610595A3 (en) 1994-09-21
HUT68498A (en) 1995-06-28
FI935847L (fi) 1994-06-25
ZA939573B (en) 1994-08-11
AU684053B2 (en) 1997-12-04
DE69324466T2 (de) 1999-11-25
DE69329400T2 (de) 2001-01-18
DE69324466D1 (de) 1999-05-20
GR3034867T3 (en) 2001-02-28
DK0867179T3 (da) 2000-11-06
NZ250541A (en) 1995-12-21
CN1094950A (zh) 1994-11-16
HU218906B (hu) 2000-12-28
ATE196081T1 (de) 2000-09-15
EP0610595B1 (fr) 1999-04-14
ES2150294T3 (es) 2000-11-16
AU5257793A (en) 1994-07-07
DE69329400D1 (de) 2000-10-12
JPH07285860A (ja) 1995-10-31
FI935847A0 (fi) 1993-12-23
NO934768L (no) 1994-06-27
IL108147A0 (en) 1994-04-12
DK0610595T3 (da) 1999-10-25
NO305932B1 (no) 1999-08-23
US5525631A (en) 1996-06-11
NO934768D0 (no) 1993-12-22
ES2132170T3 (es) 1999-08-16
HK1012577A1 (en) 1999-08-06
PT867179E (pt) 2000-12-29
CY2214B1 (en) 2002-11-08
CA2112160A1 (fr) 1994-06-25

Similar Documents

Publication Publication Date Title
US5354885A (en) Process for preparing ethyl ester of L-DOPA
US5607969A (en) L-DOPA ethyl ester to treat Parkinson's disease
RU2128160C1 (ru) Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция
US12329757B2 (en) Methods for increasing sepiapterin plasma exposure
EP2041108B1 (fr) Dérivés de médicaments de type 4-hydroxythiobenzamide
RS55142B1 (sr) Deuterisani derivati kateholamina i medikamenti koji obuhvataju pomenuta jedinjenja
HK1012577B (en) Composition of l-dopa esters
US6201011B1 (en) Therapeutic agent for allergic dermatitis
JP2022528355A (ja) Ｓ－（ｎ，ｎ－ジエチルカルバモイル）グルタチオンの塩形態
EP0310259B1 (fr) Epérisone comme agent hypotenseur
CA2884173A1 (fr) Preparations de substances medicamenteuses, compositions pharmaceutiques et formes pharmaceutiques comprenant du s-(+)-flurbiprofene
EP0555938A1 (fr) Utilisation de dérivés phénoxyacétiques pour la restauration des fonctions nerveuse
TW407141B (en) Vasomolol, an ultra short-acting and vasodilatory vanilloid type <beta>1- adrenoceptor antagonist
FR2470133A1 (fr) Nouveaux sels d'addition d'acides d'alcaloides de l'ergot et d'alcaloides du dihydro-ergot physiologiquement acceptables et amorphes aux rayons x, utiles comme medicaments et procede de leur preparation
FR2665634A1 (fr) Utilisation de derives de l'acide phenoxyacetique pour obtention d'un medicament destine a restituer le fonctionnement de la cellule nerveuse.
BE878563A (fr) Nouvelles alpha-alkyl-o-oxybenzylamines, leur preparation et leur application comme medicaments
HK1131125B (en) 4-hydroxythiobenzamide derivatives of drugs

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed